Ascendia Pharmaceuticals, a specialty contract development and manufacturing organization (CDMO) dedicated to developing and manufacturing enhanced formulations for pre-clinical, clinical stage drug candidates, and marketed drug products, has received an investment made by Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments. The proceeds will be used to fund Ascendia’s facility expansion to support the growing demand in the sector.
 
Founded in 2012, Ascendia offers a comprehensive suite of pre-formulation, formulation development, manufacturing, and stability services for parental, oral, and topical dosage forms. The company also provides analytical method development and validation services for those dosage forms. At the same time, formulation development expertise is supported by its technology platforms in nanoparticle, amorphous solid dispersion, and nano-emulsions. The company says this enables them to solve complex solubility and bioavailability challenges for a wide variety of molecules with difficult properties.
 
“We are very excited to receive this investment, which will allow us to accelerate the growth of our business to the next level,” said Jim J. Huang, CEO, Ascendia. “Signet Healthcare Partners is an ideal partner given its extensive experience and know-how in the pharmaceutical CDMO space. The expansion in the footprint and manufacturing capacity brought forth by this investment will enable us to continue to innovate and meet our growing production needs for early and late phases of product development.”
 
James Gale, managing director at Signet Healthcare Partners, said, “Ascendia has established capabilities in solving complex formulation problems and manufacturing pre-clinical and clinical trial materials for its clients. Signet looks forward to a close collaboration with Dr. Huang and the leadership team at Ascendia to support them in growing their business.”